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Abstract 
Purpose: To develop a highly sensitive and specific ultra-performance liquid chromatography with 
linear ion trap Orbitrap mass spectrometer (UPLC-LTQ-Orbitrap) method to profile and identify the 
metabolites of evodiamine in rats. 
Methods: First, blood samples were collected after oral administration of evodiamine to rats (50 mg/kg). 
Next, the plasma samples were pretreated using a solid-phase extraction (SPE) method. Finally, all the 
samples were analyzed by ultra-performance liquid chromatography LTQ-Orbitrap mass spectrometry 
(UPLC-LTQ-Orbitrap) coupled with electrospray ionization source (ESI) in negative mode. 
Results: A total of 7 metabolites (2 phase I and 4 phase II metabolites, including 4 new metabolites, viz, 
10-hydroxyevodiamine sulfate, 10-hydroxyevodiamine sulfate, 10-hydroxyevodiamine glucuronide and 
3-hydroxyevodiamine glucuronide) as well as the parent drug itself , were detected and identified based 
on accurate mass measurements, fragmentation patterns, and chromatographic retention times. The in 
vivo metabolic reactions of evodiamine in rats were hydroxylation, hydroxylation + sulfate conjugation, 
and hydroxylation + glucuronidation. 
Conclusion: These results provide better understanding of the metabolism of evodiamine as well as 
strong indications of the effective forms of the drug in vivo. 
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Evodiamine belonging to indoloquinazoline 
alkaloids, is a major constituent isolated from the 
herbal medicine Evodia rutaecarpa (Wu-zhu-yu), 
which has been officially listed in Chinese 
Pharmacopoeia [1] and widely used in China for 
more than 2000 years. Pharmacological studies 
indicate that it possesses variety of anti-
thrombotic, anti-inflammatory, uterotonic, 
thermoregulatory, anti-obesity, hypotensive, and 
vasodilatory effects [2-5]. 
 
Previous reports demonstrated that evodiamine 
had low oral bioavailability in rats [6,7], which 
suggested that evodiamine might undergo an 
extensive first-pass metabolism. 
Pharmacological studies have revealed the 
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cytotoxicity of evodiamine might be related to the 
transformation of evodiamine into its 10-
hydroxyevodiamine or other metabolites [8]. 
However, so far as we are aware, the 
biotransformation of evodiamine has not been 
fully investigated due to the limitations of 
analytical techniques [8-10]. For instance, only 
two and five metabolites were detected and 
identified in vivo and in vitro, respectively [8-11]. 
In this respect, it is important to characterize its 
metabolism profile in vivo, which can help to 
further understand the mechanism of action of 
evodiamine. 
 
During the past decade, liquid 
chromatography/electrospray tandem mass 
spectrometry was the main method for the 
structural characterization of drug metabolites in 
vivo and in vitro [12,13]. Ultra–high performance 
liquid chromatography coupled with high–
resolution mass spectrometer (UPLC-HRMS) 
such as UPLC-LTQ-Orbitrap significantly 
contributes to the characterization of drug 
metabolites due to its higher separation and 
resolution capacities in a shorter time [14,15]. 
 
The principal metabolic pathways of evodiamine 
in rats were proposed for the first time in this 
study. This study is also useful to understand the 
drug’s pharmacological effects. 
 
 




Chemicals and reagents 
 
Evodiamine was isolated from the 95 % aqueous 
ethanolic extract of Euodiae Fructus in our 
laboratory. Its structure was identified by 
comparing their UV, MS, 1H-NMR and 13C-NMR 
data with it’s in the literature. Its purity was > 98 
% by HPLC analysis. The structure is displayed 
in Figure 1. Grace PureTM SPE C18 phase 
extraction cartridges (200 mg/3 mL, 59 μm, 70 Å) 
were purchased from Grace Davison Discovery 
ScienceTM (Deerfield, IL, USA). Ultra-pure water 
used throughout the experiment was freshly 
prepared using a Milli-Q water purification 
system (Millipore, Billerica, MA, USA). 
Acetonitrile was of HPLC-grade (Fisher, NJ, 
USA). All other chemicals and reagents were of 
analytical grade and commercially available. 
 
Animals and drug administration 
 
Six male Sprague-Dawley rats (weighing 200 – 
250 g) were supplied by Beijing Weitong Lihua 
Experimental Animals Company (Beijing, China) 
and housed in controlled environmental 
conditions (temperature, 24 ± 2 oC; relative 
humidity, 70 ± 5 %) with free access to food and 
water in a week for acclimatization. The rats 
were randomly divided into two groups: Group A 
(n = 3), drug group for plasma; Group B (n = 3), 
control group for blank plasma. Before the 
experiment, all rats were fasted for 12 h and fed 
with water. Evodiamine was suspended in 0.5 % 
carboxymethylcellulose sodium (CMC-Na) 
aqueous solution. The rats from group A were 
anesthetized with ether at 2 h after oral 
administration of evodiamine at a dose of 100 
mg/kg body weight and then sacrificed by 
decapitation. The rats from group B were oral 
administrated with 0.5 % CMC-Na aqueous 
solution in the same way. The blood were 
withdrawn in heparinized centrifuge tubes and 
centrifuged at 4000 rpm for 10 min to obtain the 
plasma. All plasma samples were stored at – 20 
°C until other pretreatment and analysis. The 
animal experiments were carried out in 
accordance with the guidelines for Animal 
Experimentation of Hunan University of 
Medicine, and the protocols were approved by 
the Animal Biomedical Ethical Committee of 





All plasma samples were pretreated by a solid-
phase extraction (SPE). An SPE cartridge was 
pretreated with 5 mL of water, 5 mL of methanol 
and 5 mL of water, successively. 1 mL sample of 
plasma was loaded, and allowed to flow through 
the SPE cartridge with gravity. The SPE cartridge 
was washed with 5 mL of water and 5 mL of 
methanol, successively. The methanol eluate 
was collected and evaporated to dryness under 
N2 at room temperature. The residue was re–
dissolved in 100 µL of acetonitrile/water (10:90, 
v/v) and centrifuged at 12,000 rpm at 4 oC for 30 
min. A volume of 2 µL supernatant was injected 
into UPLC-LTQ-Orbitrap MS for analysis. 
 
Instrumentation and conditions 
 
All LC/MS analyses were performed on a 
Finnigan LTQ/Orbitrap (Thermo Electron, 
Bremen, Germany) coupled to an ESI source 
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(Thermo Electron, Bremen, Germany). A Waters 
ACQUITY BEH C18 column (2.1 × 100 mm i.d., 
1.7 μm) was used for separation of the 
metabolites at room temperature and a flow rate 
of 0.3 mL/min. The mobile phase consisted of 
water (solvent A) and acetonitrile (solvent B) 
using a gradient elution as follows: 0 – 2 min, 5 
% B; 2 – 3 min, 5 – 10 % B; 3 – 25 min, 10 – 35 
% B; 25 – 30 min, 35 – 80 % B; 30 – 35 min, 80 
% B; 35 – 36 min, 80 – 5 % B; 36 – 40 min, 5 % 
B.  
 
Samples were analyzed in the negative mode 
with the tune method set as follows: sheath gas 
(nitrogen) flow rate of 30 arb, aux gas (nitrogen) 
flow rate of 5 arb, spray voltage of 4.0 kV, 
capillary temperature of 350 ℃, capillary voltage 
of 25 V, tube lens voltage of 110 V.  
 
In the full scan experiment, resolution of the 
Orbitrap mass analyzer was set at 30,000 and 
with a mass range of m/z 100 – 800. Data-
dependent MS/MS scanning was performed to 
minimize total analytical time as it can trigger 
fragmentation spectra of target ions. The collision 
energy for collision induced dissociation (CID) 
was adjusted to 30 % of maximum, and the 
isolation width of precursor ions was m/z 2.0 Da.  
 
Peak selections and data processing 
 
Thermo Xcaliber 2.1 workstation was used for 
the data acquisition and processing. In order to 
obtain as many fragment ions of the metabolites 
as possible, the peaks detected with intensity 
over 10,000 were selected for identifications. The 
chemical formulas for all parent ions of the 
selected peaks were calculated from the 
accurate mass using a formula predictor by 
setting the parameters as follows: C [0 – 30], H 
[0 – 50], O [0 – 20], S [0 – 4], N [0 – 4], Cl [0 – 4], 
and ring double bond (RDB) equivalent value [0 
– 15]. Other elements such as P and Br were not 
considered because they are rarely present in 




Fragmentation pathway of evodiamine 
 
In order to facilitate the structural identification of 
the metabolite, the MSn fragmentation pattern of 
evodiamine was investigated [17]. The parent ion 
showed a deprotonated ion [M-H]- at m/z 
302.1296 (2.8 ppm, C19H16ON3) in negative 
mode. Fragmentation of the parent ion provided 
characteristic fragment ions at m/z 169.0765 (2.5 
ppm, C11H9N2) and m/z 142.0658 (4.7 ppm, 
C10H9N) by the loss of the moieties C8H7ON and 
C8H7ON +CNH, respectively, which were useful 
information in metabolite identification. Besides, 
the fragment at m/z 142 can be formed by loss of 
CNH from the ion at m/z 169 in the MS3 spectra. 
The MSn spectrum of evodiamine was shown in 
Figure 2. 
 
Detection and structural elucidation of 
metabolites 
 
After comparison the high-resolution EIC 
(HREIC) of the drug samples with corresponding 
control samples, a total of 7 metabolites as well 
as the parent drug were detected and identified. 
The HREIC of drug sample is shown in Figure 3. 
The chromatographic and mass spectrometric 
data of the parent drug and its metabolites are 




Metabolite M0 was unambiguously identified as 
evodiamine by comparing the retention time, 
accurate MS and MS/MS spectra with the 
authentic reference. 
 
Metabolites M1 and M2 
 
Metabolites M1 and M2 were eluted at 17.42 and 
19.29 min with the quasi-molecular ions of m/z 
318.1248 (3.6 ppm, C19H16O2N3) and m/z 
318.1245 (2.6 ppm, C19H16O2N3), 16 Da more 
than that of evodiamine, indicating that it might 
be the product of mono-hydroxylated of the 
prototype drug. This ion at m/z 185 in M1 MS2 
spectra was found to be characterization for the 
presence of a hydroxyl group at one of the 
positions of the aromatic ring of the indole 
moiety. Based on these results, metabolite M1 
were proposed to be mono-hydroxylated on the 
indole ring. This ion at m/z 169 in M2 MS2 
spectra belonged to the aromatic ring of the 
indole moiety, suggesting that metabolite M2 
were proposed to be no mono-hydroxylated on 
the indole ring. Previous reports [11] showed that 
the metabolites 10-hydroxyevodiamine and 3-
hydroxyevodiamine of evodiamine is easy to 
produce, therefore, M1 and M2 were tentatively 
identified as 10-hydroxyevodiamine and 3-
hydroxyevodiamine, respectively. 
 
Metabolites M3 and M4 
 
Metabolites M3 and M4, possessing the same 
deprotonated molecular ion [M–H]– at m/z 
398.0813 (2.0 ppm, C18H12O5N3S), were 
detected at 15.81, and 16.44 min, respectively. 
This fragment ion at m/z 318 was observed by  
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  Figure 2: The MSn specturm of evodiamine 
 
 
Figure 3: High-resolution EIC in 5 ppm for the multiple metabolites in rat plasma m/z 302.1288, 318.1237, 
398.0805, and 494.1558 
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loss 80 Da than the precursor ion at m/z 398 in 
their MS2 spectra, suggesting the presence of 
one sulfate residue in. The MS3 of M3 and M4 
possessed the same MS2 spectra with M1 and 
M2, respectively, suggesting the core structure of 
M3 and M4 were mono-hydroxylated of 
evodiamine. Therefore, M3 and M4 were 
tentatively characterized as 10-
hydroxyevodiamine sulfate and 3-
hydroxyevodiamine sulfate, which were new 
metabolites. 
 
Metabolites M5 and M6 
 
Metabolites M5 and M6 were eluted at 12.19, 
and 12.68 min, with the quasi-molecular ions of 
m/z 494.1573 (3.2 ppm, C25H24O8N3), and m/z 
494.1575 (3.4 ppm, C25H24O8N3). This 
characteristic ion at m/z 318 was observed by 
loss 176 Da than the precursor ion at m/z 494 in 
their MS2 spectra, which indicated that they 
might be products of glucuronide conjugation of 
M1 and M2. Analyzing the clogP values of their 
potential metabolites, M5 and M6 were 
tentatively assigned as 10-hydroxyevodiamine 
Sulfate and 3-hydroxyevodiamine sulfate, which 
were new metabolites. 
 
Proposed metabolic pathways of evodiamine 
 
In this study, 7 metabolites (4 new) as well as 
parent drug itself were detected in the plasma. 
The proposed major metabolic pathways of 
evodiamine in the rat plasma are demonstrated 
in Figure 4. In general, the metabolism of 
evodiamine in vivo was firstly undergone 
hydroxylation metabolic reactions (M1–M2), and 
then sulfate conjugation (M3–M4) and 
glucuronide conjugation (M5–M6) were taken 




An UPLC-LTQ-Orbitrap mass spectrometry 
method for analysis the metabolites of 
evodiamine was established at first. In order to 
obtain an appropriate elution system, mobile 
systems such as acetonitrile – water and 
methanol – water were tested. The result 
demonstrated that acetonitrile – water with a 
gradient elution mode could afford better 
resolution of chromatographic peaks among the 
metabolites and endogenous components. 
 
The evodiamine metabolites under investigation 
belong to indoloquinazoline alkaloids, which 
make it predestined detection by ESI in positive 
mode. However, Negative mode was selected for 
ESI-MS analysis in this study, as it provided 
more intensity response and less mass spectral 
interference [16]. To our best knowledge, the 
biotransformation of evodiamine has been poorly 
understood, although some works on the 
metabolism of evodiamine have already been 
performed [8–11]. For example, only one and two 




Figure 4: Proposed major metabolic pathway of evodiamine in rats 
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H]- MS/MS fragment Identification 
M0 26.05 302.1288 302.1296 2.8 C19H16ON3 





M1 17.42 318.1237 318.1248 3.6 C19H16O2N3 
MS2 [318]: 185(100), 
158(15) 10-hydroxyevodiamine 
M2 19.29 318.1237 318.1245 2.6 C19H16O2N3 
MS2 [318]: 169(100), 
142(8) 3-hydroxyevodiamine 
M3 15.81 398.0805 398.0813 2.0 C19H16O5N3S 
MS2 [398]: 318(100) 
MS3 [318]: 185(100), 
158(8) 
10-hydroxyevodiamine Sulfate 
M4 16.44 398.0805 398.0813 2.0 C19H16O5N3S MS
2 [398]: 318(100) 
MS3 [318]: 169(100) 3-hydroxyevodiamine Sulfate 
M5 12.19 494.1558 494.1575 3.4 C25H24O8N3 
MS2 [494]: 
318(100),175(22) 10-hydroxyevodiamine Glucuronide 
M6 12.68 494.1558 494.1573 3.2 C25H24O8N3 
MS2 [494]: 
318(100),175(42) 3-hydroxyevodiamine Glucuronide 
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urine and feces of SD rats by comparing the 
retention time and mass spectrometry of 
metabolites from Microbial biotransformation 
[8,11]. Five metabolites were tentatively detected 
and characterize in human liver microsomes. It is 
worth mentioning that none metabolites was 
detected in rat plasma including parent drug. In 
our study, 7 metabolites including parent drug 
itself were detected and identified in rat plasma. 
However, the previously reported metabolite 
named N-demethylated evodiamine was 
undetected in both positive and negative MS 
modes in the present experiment, which might be 




By online LC-MSn data acquisition and offline 
data processing methods of the software 
Xcalibur 2.1, a total of 7 metabolites were 
detected and identified based on accurate mass 
measurements, the fragmentation patterns and 
chromatographic retention times. The findings 
show that the profile of the metabolites of 
evodiamine in rats can provide greater insight 
into its pharmacological effects, metabolic fate in 
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